BMC Infectious Diseases (Feb 2024)

Quality control and external quality assessment for the independent clinic-based evaluation of point-of-care testing to detect Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in eight countries

  • Mark Shephard,
  • Susan Matthews,
  • Kelly Andrewartha,
  • Wayne Dimech,
  • Liza Cabuang,
  • Christopher Barbara,
  • Xiang-Sheng Chen,
  • Maddalena Cordioli,
  • Amina Hançali,
  • Ting-Ting Jiang,
  • Ranmini Kularatne,
  • Stephanie Meli,
  • Etienne Muller,
  • Hicham Oumzil,
  • Valeska Padovese,
  • Angela Sandri,
  • Silver Vargas,
  • Graziella Zahra,
  • Magnus Unemo,
  • Karel Blondeel,
  • Igor Toskin

DOI
https://doi.org/10.1186/s12879-024-09057-x
Journal volume & issue
Vol. 24, no. S1
pp. 1 – 11

Abstract

Read online

Abstract Background Sexually transmitted infections caused by Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Trichomonas vaginalis (TV) remain significant global health problems. The World Health Organization (WHO) has recently conducted a multi-faceted, multi-country validation study (ProSPeRo), which included an evaluation of the Xpert CT/NG and Xpert TV assays on the GeneXpert system (Cepheid, Sunnyvale, Ca., USA) in clinic-based settings across eight countries. To support the study, a training and quality management system was implemented and evaluated. Methods A comprehensive training program for the study was developed. Quality control (QC) and external quality assessment (EQA) samples were provided by an accredited quality assurance provider. QC testing was conducted at 14 point-of-care testing (POCT) clinics, while EQA samples were tested by the POCT sites and a reference laboratory supporting each clinic. Results For QC testing, concordance with the expected results for CT and NG was > 99% and rates of unsuccessful tests were 94%) for all analytes, but this cohort (which used GeneXpert systems) exhibited a high rate of unsuccessful TV tests. All but one of these unsuccessful tests was subcategorised as ‘invalid’. Conclusions The high level of concordance for QC and EQA testing confirm that the trained operators at the POC clinical sites were competent to conduct POC testing and that the training and quality systems implemented for the ProSPeRo study were effective. The quality materials used were satisfactory for CT and NG but exhibited poor performance for TV testing on the GeneXpert system. The WHO should continue to work with industry and EQA providers to provide improved materials that are reliable, stable and cost effective for quality management, as it seeks to rollout molecular-based STI POCT in non-laboratory-based settings. Trial registration Ethics approval to conduct the ProSPeRo study was granted by the WHO Ethics Review Committee.

Keywords